GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting
GRAIL (Nasdaq: GRAL) will present late-breaking NHS-Galleri and PATHFINDER 2 results at the 2026 ASCO Annual Meeting, May 29–June 2 in Chicago.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
GRAIL (Nasdaq: GRAL) will present late-breaking NHS-Galleri and PATHFINDER 2 results at the 2026 ASCO Annual Meeting, May 29–June 2 in Chicago.
The NHS-Galleri randomized trial screened >142,000 participants; PATHFINDER 2 includes >32,000 evaluable participants, >174,000 combined, with oral presentations on May 30–31, 2026.
Positive
- NHS-Galleri randomized trial enrolled >142,000 participants
- PATHFINDER 2 includes >32,000 evaluable participants
- Combined evidence base exceeds >174,000 participants
- Late-breaking oral presentations at ASCO indicate high scientific priority
Negative
- None.
Details
News Market Reaction – GRAL
On Apr 22, the first trading day after this news, GRAL closed 3.04% above the previous close.
Data tracked by StockTitan Argus for the Apr 22 session.
Key Figures
- Total participants
- More than 174,000 participants
- Combined enrollment across NHS-Galleri and PATHFINDER 2 studies
- NHS-Galleri participants
- More than 142,000 participants
- Randomized trial within England's NHS, ages 50 to 77
- Age range
- Aged 50 to 77
- Demographically representative NHS-Galleri study population
- PATHFINDER 2 dataset size
- More than 32,000 evaluable participants
- Largest MCED interventional study in North America in intended-use population
- ASCO meeting dates
- May 29–June 2, 2026
- Timing of 2026 ASCO Annual Meeting where data will be presented
- Price vs 52-week high
- -57.04%
- GRAL share price relative to 52-week high of 118.84 before this news
- Price vs 52-week low
- 99.73%
- GRAL share price relative to 52-week low of 25.56 before this news
- Market capitalization
- $2,100,237,056
- Equity value prior to ASCO data announcement
Historical Context
-
Integration of Galleri test into Epic EHR across ~450 health systems.
-
Partnership with Superpower to offer Galleri via preventative health platform.
-
Retirement of CEO Bob Ragusa and appointment of Josh Ofman as successor.
-
Inducement RSU awards to new hires under equity incentive plan.
-
Announcement of company presentation at TD Cowen health care conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
multi-cancer early detection (MCED) medical
randomized controlled study medical
investigational device exemption regulatory
ctDNA medical
block trade financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Detailed NHS-Galleri Trial Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation
Final PATHFINDER 2 Study Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation
More than 174,000 Participants Enrolled Across Both Studies, Demonstrating the Scientific Rigor of Galleri® Clinical Development Program
The NHS-Galleri trial presentation will expand on topline results announced in February 2026. The NHS-Galleri trial, the first and only randomized controlled study of an MCED test, was designed to demonstrate population-level impact through the reduction of late-stage cancer diagnosis and increased cancer detection rate within
Building on initial results presented at the European Society for Medical Oncology (ESMO) Congress in October 2025, the complete PATHFINDER 2 dataset of more than 32,000 evaluable participants will be presented. Conducted under an FDA-approved investigational device exemption, PATHFINDER 2 is the largest MCED interventional study in
"The goal of cancer screening is to detect cancer before it becomes advanced or spreads, when treatment options may be broader, care and cost may be less intensive, and the opportunity for cure is often greater. Yet the status quo still leaves too many cancers unscreened. In the
ASCO Presentations
Title: NHS-Galleri: Primary results from a randomised controlled trial to assess the clinical utility of a multi-cancer early detection (MCED) test in population screening
Abstract Number: LBA100
Session Title: Clinical Science Symposium - ctDNA in Clinical Practice: From Detection to Clinical Decision-Making
Presentation type: Oral Presentation
Date/Time: Saturday, May 30, 2026 – 8:12-8:24 am CDT
Title: Safety and performance results from PATHFINDER 2 (PF2), a registrational study of a multi-cancer early detection (MCED) test in an intended-use population
Abstract Number: LBA10509
Session Title: Rapid Oral Abstract Session - Prevention, Risk Reduction, and Genetics
Presentation type: Oral Presentation
Date/Time: May 31, 2026 – 9:45-9:52 am CDT
Title: Implementation of a multi-cancer early detection (MCED) test in a private practice: adoption, performance, and repeat-testing patterns
Abstract Number: 10532
Presentation Type: Poster #493
Date/Time: June 1, 2026 – 1:30-4:30 pm CDT
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
About Galleri®
The Galleri multi-cancer early detection test is a proactive tool to screen for cancer. With a simple blood draw, Galleri can detect more than 50 types of cancer before symptoms appear — when they can be easier to treat and are potentially curable2. Galleri is the only available MCED test with demonstrated performance in patients screened for cancer2*. The Galleri test increases the number of cancers detected seven-fold when added to recommended screening for breast, cervical, colorectal and lung cancers, and has the lowest false positive rate of any MCED test on the market1,2,3,4,**The Galleri test doubles the number of cancers detected when added to standard of care cancer screening, and has the lowest false positive rate of any MCED test1,2,3,4**. When a cancer signal is found, Galleri provides a cancer signal of origin with high accuracy to help guide an efficient diagnostic work-up4,5,6. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.
For more information, visit galleri.com.
* The Galleri test performance metrics were derived from the outcomes of an interventional clinical study of patients presenting for screening without clinical suspicion of cancer, a study population that reflects the intended use population.
** Test performance metrics do not represent results of a head-to-head comparative study. Separate studies have different designs, objectives, and participant populations, which limits the ability to draw conclusions about comparative performance.
Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory/Test Information
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
GRAIL Forward Looking Statements
This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," "would," or "will," the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include statements related to the potential benefits, uses and impacts of the Galleri test, our expectations regarding the results and outcomes of the NHS-Galleri trial and the PATHFINDER 2 study, the potential clinical utility, performance and safety profile of the Galleri test, the impact of clinical evidence on adoption into practice, cancer screening, public health and patient outcomes, among others.
These statements are only predictions based on our current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors and numerous associated risks discussed under the section entitled "Risk Factors" in our Annual Report on Form 10-K for the period ended December 31, 2025. Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements we may make.
Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Although we believe the expectations and projections expressed or implied by the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Our actual results, financial condition and success in our business strategies and operations may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, we undertake no obligation to update any of these forward-looking statements after the date of this press release to conform our prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events.
References:
- Nabavizadeh N, et al. Safety and Performance of a Multi-Cancer Early Detection (MCED) Test in an Intended-Use Population: Initial Results from the Registrational PATHFINDER 2 Study. Proffered Presentation Presented at: European Society for Medical Oncology (ESMO) Annual Meeting; October 17-21, 2025;
Berlin, Germany . - Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
- GRAIL, Inc. False positive rate. [Data on file: GR-2025-0256]
- Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251-1260. doi: 10.1016/S0140-6736(23)01700-2
- GRAIL, Inc. Enhanced Cancer Signal Origin prediction. [Data on file: VV-TMF-59592]
- Hackshaw A, et al. Cancer Cell. 2022;40(2):109-13.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-new-data-from-nhs-galleri-and-pathfinder-2-at-2026-asco-annual-meeting-302749354.html
SOURCE GRAIL, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.